United Alaskan Klee Kai Association, Inc
Dedicated to protect, promote, and advance the
best interests, health, and welfare of

purebred Alaskan Klee Kai

 


Melody, Jazz and Harmony of Eileen Gregory of Alascos Klee Kai Kennelette and Jim and Marilyn of Helderbergs Huskies

HOME

President :
Barbara Williams
Vice President:
Mike Carlin
Secretary:
Julie Baker
Treasurer:
Sheila Sweet
Membership Secretary:
Linda Yates
Director:
Desarie Fletcher

Director:
Janet Mann


 

NEWS
Old News
Election NewsNEW!
Top Ten for UKC


Blue bred by Widdershin Estates


 


Pair of Red Males by H.O.T. AKK

Club Information
Historical Club Calendar
News Previously on the
Front Page

Activities & Events
Newsletters
First AKK Specialty
Association Meetings


 

Committees
Officers and Directors

Member Application
Member Directory
UAKKA AKK Gallery

Show Committee


Breed Information
Breed Standard
Breeders List  NEW!!
AKK and Activities
Whelping Calendar

Health Issues
FVII
Ads & Merchandise

 

 

REMEMBER The Following that has ALWAYS been recommended by U of Pa.

FVII deficiency in Alaskan Klee Kai dogs causing a MILD bleeding disorder

PLEASE  View Others Results and Post Yours @

WWW. ALASKANKLEEKAI.INFO

IMPORTANT POINTS FROM DR. GIGER TO REMEMBER :

NO ALASKAN KLEE KAI WILL DIE FROM FACTOR VII.
 
NO AKK Should be altered SOLEY on Factor VII test results. 

 
This is a mild disorder that only creates an issue when it is combined with other issues

 

Report From AKKAOA Specialty Seminar

Dr. Urs Giger's presentation in Shelbyville, KY (Nov 4, 2006) about hereditary diseases in dogs, and specifically Factor VII Deficiency in the Alaskan Klee Kai, answered many questions, but also raised additional questions for us. It is becoming increasingly clear that this may be a very mild bleeding tendency in the Alaskan Klee Kai, apparently less severe than in Beagles – the first breed found with this bleeding disorder - and much less severe than in Scottish Deerhounds. Discrepancies in test results that are being reported, such as a Carrier status from 2 Clear parents, may be due to errors in labeling of samples (by owner or by lab personnel), in pedigree, inappropriate cheek swab technique, or by other factors not yet understood.  In order to learn more about this disease, which seems to be a first joint health approach for this breed, we need to continue to gather more information. Here are Dr. Giger’s studies on AKK at PennGen.

Correlation between DNA test results and Bleeding Tendency:

Ideally, Alaskan Klee Kai found to be Affected/Factor VII deficient by DNA testing should also be tested by a PT, PTT and FVII analysis. This can be accomplished through PennGen or the Cornell Comparative Hemostasis Laboratory. For these studies EDTA and citrated plasma (immediately after collection in a proper ratio of 9 parts blood and 1 part citrate sample need to be mixed, spun and the plasma transferred into a well sealed, labeled tube) should be collected at the same time and shipped on (dry) ice in a double ziplock-type bag inside a safe container by overnight mail early in the week to the laboratory.  There are many laboratories and even clinics that can run a PT and PTT but many do not have established normal ranges or their normal ranges are wide and may miss Affecteds by these screening tests.  If they are sent to PennGen with the appropriate information, including a description of the presence or absence of an increased bleeding tendency, we will do these studies for the first 20 samples from Affected (Factor VII deficient) Alaskan Klee Kai free of charge. Again, results will be kept confidential, but are provided to the sender of the sample or owner of the dog.

SNP Breed Profile for Alaskan Klee Kai:

The Alaskan Klee Kai is a novel breed with relatively few ancestors. Because of the narrow gene pool and the likely use of a few major breeding pairs, certain diseases may be seen more frequently in the breed. A good example is factor VII deficiency for which there are already reliable biochemical and DNA tests.  For other diseases, little to no information is currently available.  In order to better define the breed at the DNA level, and to have tools to tackle some of the hereditary diseases in the breed in the near future, a breed profile with SNPs would be desirable. SNP profiles are available for many breeds and screening mud dogs to determine the origin and contribution of a particular mixed breed dog is becoming commercially available.  In order to get a SNP profile for Alaskan Klee Kai, EDTA blood samples from all the different original dogs and major lines should be analyzed. Efforts are being made to collect these samples by the Alaskan Klee Kai breed clubs in order to assure coverage. The details of the SNP profile will not be made available for any specific dog but used to establish a breed profile to test others. 

Meanwhile, be cautious and well informed when making breeding decisions.  Best to screen any dog that will be used for breeding, and breed Carrier to Clear, or, obviously, Clear to Clear, and you may want to make those decisions based on these results and the desirable traits of the dog.

Other than the original puppy with whom all this investigation started, there have been no other reports of serious bleeding tendency in the Alaskan Klee Kai, so everyone is doing a really good job of testing their dogs and keeping "on top of" any potential bleeding problems that may exist.  With all these efforts described above it is hoped to prevent and/or identify any Factor VII deficient dogs in order for them to receive the appropriate treatment. Indeed, plasma transfusions and, potentially, recombinant human factor VIIa, may be helpful in addition to the use of excellent local hemostasis.

 This report reviewed and edited by Dr Giger & submitted by Lo Binkley for  AKKAOA,Inc and UAKKA, Inc

 

 

REMEMBER The Following that has ALWAYS been recommended by U of Pa.

FVII deficiency in Alaskan Klee Kai dogs causing a MILD bleeding disorder

PLEASE  View Others Results and Post Yours @

WWW. ALASKANKLEEKAI.INFO

IMPORTANT POINTS FROM DR. GIGER TO REMEMBER :

NO ALASKAN KLEE KAI WILL DIE FROM FACTOR VII.
 
NO AKK Should be altered SOLEY on Factor VII test results. 

 
This is a mild disorder that only creates an issue when it is combined with other issues

 

May 15th Factor VII Deficiency Information Update

 

May 3, 2006

Dear Barbara and Members of the Alaskan Klee Kai  community,

Just a couple of months ago the first Alaskan Klee Kai  with excessive
hemorrhage associated with Factor FVII (FVII) deficiency has been  identified
and since then a screening program has been established and is being  offered to the
Klee Kai community through the Josephine Deubler Genetic Disease  Testing
Laboratory at the University of Pennsylvania.

Incidentally, Dr, Deubler, in whose honor we named the lab, was  the first
female veterinary student who graduated from Penn, and is still very  much known
and respected for her communications, understanding and liaison  between
veterinarians and breeders as well as a judge at most dog shows  including Best
of Show judge at the Westminster Dog Show in Madison Square  Garden NY and
organizer of the Bucks and Montgomery dog shows for decades. Today  is Dr.
Deublers 89th birthday and as every other day she is at work in her  office
finalizing all the organization for this weekends Bucks County Dog Show  near
New Hope PA on Saturday.

While we have received a large number  of samples from Klee Kai, we need a
little more time to better understand the  distribution of the FVII mutation in
the breed and the impact on the breed.  Nevertheless I was asked to reiterate
a few previously made statements and to  answer some questions.


*   FVII deficiency results in a mild bleeding tendency just like in
people  and other breeds. We have identified several deficient Klee Kais, but
none had  exhibited the serious bleeding events as the first Klee Kai studied.
Hence this bleeding disorder may remain asymptomatic in many dogs and it
appears likely that other conditions may influence the bleeding tendency; for
instance the smaller size of the breed may protect them from serious bleeding
episodes.  Based upon the information we have FVII deficient Klee Kais  are
expected to reach a near normal life expectancy, however, at times of  surgery
and trauma and when exposed to anticoagulants, such as rodenticides or  heparin,
or certain other drugs affecting hemostasis (Aspirin) they may bleed  more
severally and may need even require blood product support.  Knowing  what the
hemostatic defect is will help the veterinarian to treat most  appropriately and
to avoid the use of harmful drugs.
 

*   Our DNA test is specific for the mutation identified in FVII
deficient  Klee Kai and detects not only deficient (homozygous) but also carrier
and normal/clear Klee Kai.  Carriers, who have one normal and one  mutant/diseased
gene/allele, have normal coagulation and routine coagulation  tests and are
therefore not at risk for bleeding.  Any breed club would  be delighted to have
a DNA test to screen for a particular disease or trait  rather than to have
to base their evaluations and decisions on physical  examination or other
tests, which are generally incapable of differentiating  accurately carriers
from normals and are also requiring special overnight  shipments on dry ice of
specific samples.
    

*   Although DNA testing is the most accurate method for identifying
genetic  diseases, no test can be a 100% accurate as humans are involved in
collecting,  labeling, testing, and reporting results.  Over the more than 10
years of  genetic disease testing we have very rarely observed errors in identifying
  sires (and dams) and puppies for collection of samples as well as
mislabeling  of blood tubes and brushes by breeders and pet owners, and errors
in testing  or reporting of results.  As far as we know there are two publicized
cases regarding FVII testing of Klee Kai and these are the only ones we know
ourselves. The original samples received on a Klee Kai puppy and supposed
parents tested repeatedly as we reported them.  There is potentially a  second case
where the offspring tested as carrier and the parents as normal,  and we are
following up on that one.
    

*   While you are likely not expecting that your physician or local
veterinarian is emailing your or your dog's test results, or that the human or
a veterinary testing lab is discussing test results with you, we have been
trying to accommodate these special requests, assist the breeders as much as  we
can and provided results as soon as they become available.  Clearly  emailing
everyone is additional work and introduces another potential site for
reporting errors.  In the early phase of testing we recommend testing of  all
breeding animals until one has assurance that they are free by descent. If  there are
any potential inconsistencies please let us know as we have been  examining
any inquiries.  However, spreading rumors on the list serves  and web sites does
not help the cause, particularly not with breeders who  politicize and
apparently share some animosity against each other.  Hence  please be kind to
each other as we all only want to help the Klee Kai now and  in the future.
    

*   In order to get good DNA results we must require excellent cheek swab
  samples.  While some breeders are consistently providing excellent brush
samples others are of poor quality and require difficult, expensive, and
time-consuming additional steps to get any DNA.  This clearly delays  these
results but also other samples (there are two research specialists  testing your dogs)
and bears potential additional risks of problems with test  results.  Hence
please carefully follow the instructions and turn and rub  the brush ten times
against the cheek and let the brush completely dry before  shipping.
    

*   In order to get a better understanding of the severity of the
bleeding  tendency and what breeding options are most appropriate considering
the small size and gene pool in the breed, the frequency of the trait, and the
severity of the disease more information needs to be gathered and then
analyzed. Until such time it appears prudent to not make any breeding  decisions on
FVII test result of a single animal.     
 

*   We appreciate the great interest by the Klee Kai community in this
mild  bleeding disorder and very much hope that a calm analysis of  the test
results will lead to generally accepted breeding guidelines and a healthy Klee
Kai breed.  This DNA test is a first example for your breed from which  one
can learn and get prepared to screen for other potentially more serious
disorders that might exist in the Klee Kai as in so many other breeds.
We are pleased to be part of the health management of the Alaska Klee  Kai
and hope that our work will reduce the risk of bleeding in the  breed.

Best of luck

Urs Giger
 

 

March 15 2006 Factor VII Information update

FVII deficiency in Alaskan Klee Kai dogs causing a mild bleeding disorder

Please post and view others results at www.alaskankleekai.info

 

Several hereditary bleeding disorders have been identified in many different canine breeds and involve clotting (coagulation) factor deficiencies, platelet disorders, and von Willebrand disease. Coagulation factor VII (FVII) deficiency has been known to occur in Beagles for decades, and there are a few reports of FVII deficiency in the Alaskan Malamute, Bulldog, and a mixed breed dog. Very recently hereditary FVII deficiency was identified in a bleeding Alaskan Klee Kai dog and its family, as well as unrelated asymptomatic Alaskan Klee Kai dogs. A DNA test to identify the mutation responsible for FVII deficiency in Alaskan Klee Kai dogs has been developed at the University of Pennsylvania.

Dogs with hereditary FVII deficiency may exhibit an increased bleeding tendency following trauma or surgery or rarely appear to develop spontaneous bleeding. There are few reports of severe bleeding requiring blood transfusions, and some FVII-deficient dogs may remain unrecognized. As this is an autosomal recessive disorder, the diseased/mutant gene (allele) may be unknowingly passed on through generations not only via asymptomatic carriers but also affected dogs, as they may not show obvious signs. Carriers have one mutant and one normal gene and appear clinically normal, but they can pass the defective gene to their offspring. Only a small number of Alaskan Klee Kai dogs have been tested thus far, and hence the frequency and bleeding tendency remain to be elucidated.

Screening Alaskan Klee Kai dogs with a clotting test (PT assay) may suggest FVII deficiency, and measurement of plasma FVII coagulant activity could confirm a diagnosis of FVII deficiency. Results of the PT assay are normal for carriers, and measurement of plasma FVII coagulant activity will not accurately identify carriers, as there is overlap of FVII activities between carrier and normal dogs.

A mutation-based DNA test to screen Alaskan Klee Kai dogs (and Beagles) for FVII deficiency has been developed (Dr. Beth Callan, principal investigator) and has then been established at the Josephine Deubler Genetic Disease Testing Laboratory of the University of Pennsylvania School of Veterinary Medicine (Dr. Urs Giger, director; Mr. Adam Seng, Research Specialist). This test can clearly identify affected, carrier, and normal (also known as clear) Alaskan Klee Kai dogs. We recommend testing of any Alaskan Klee Kai dog with signs of bleeding, as well as its relatives. Furthermore, it is advisable to screen any Alaskan Klee Kai dog, particularly popular sires, prior to breeding to limit the spread of this bleeding disorder. Carriers could still be used in future breeding programs. Knowing which dog is a carrier or normal (clear) will allow the targeted breeding of carriers with desirable traits to normal dogs without ever producing affected dogs, as long as the offspring are also tested and only clear dogs used thereafter. With a breed of this size you cannot afford to neuter all animals with a mutant gene, as you want to preserve their desirable traits and the gene pool.

The Josephine Deubler Genetic Testing Laboratory at the University of Pennsylvania is offering screening for FVII deficiency in Alaskan Klee Kai dogs at a reduced introductory rate of $50 per dog through May 31, 2006 , provided that a pedigree and adequate clinical information on the submission form are included ($75 per sample without pedigree). Samples suitable for this DNA test include 1-2 mls EDTA-anticoagulated blood (preferable) or 2-3 cheek swabs (obtained with special cytology brushes). Cytology brushes and test submission forms are available through the United Alaskan Klee Kai Association ( http://www.uakka.com ) and the Alaskan Klee Kai Association of America ( http://akkaoa.org ). Test submission forms may also be downloaded from our website http://www.vet.upenn.edu/penngen . We are also offering test kits when requested with a self-addressed stamped envelop. For more information on canine FVII deficiency, please contact Dr. Beth Callan (215-898-3999; callan@vet.upenn.edu ) or Dr. Urs Giger (215-898-8830; penngen@vet.upenn.edu ). Blood and dried cheek swab samples, along with test submission forms and pedigrees, may be submitted in a ziploc bag to Dr. Urs Giger/FVII Rm 4006, Ryan Veterinary Hospital, University of Pennsylvania, 3900 Spruce Street, Philadelphia, PA, 19104-6010. Test results are generally available within 3 weeks of receipt of samples and are sent only to submitter of samples. All information is kept strictly confidential.

Directions for taking a sample

Submission Form And Instructions

 

About Factor VII Deficiency in the Alaskan Klee Kai

February 28, 2006

 

FVII deficiency in Alaskan Klee Kai dogs causing a mild bleeding disorder

 

Several hereditary bleeding disorders have been identified in many different canine breeds and involve clotting (coagulation) factor deficiencies, platelet disorders, and von Willebrand disease.  Coagulation factor VII (FVII) deficiency has been known to occur in Beagles for decades, and there are a few reports of FVII deficiency in the Alaskan Malamute, Bulldog, and a mixed breed dog.  Very recently hereditary FVII deficiency was identified in a bleeding Klee Kai dog and its family, and a DNA test to identify the mutation responsible for FVII deficiency in Alaskan Klee Kai dogs has been developed at the University of Pennsylvania.

 

Dogs with hereditary FVII deficiency may exhibit an increased bleeding tendency following trauma or surgery or rarely appear to develop spontaneous bleeding.  There are few reports of severe bleeding requiring blood transfusions, and some FVII-deficient dogs may remain unrecognized.  As this is an autosomal recessive disorder, the diseased/mutant gene (allele) may be unknowingly passed on through generations not only via asymptomatic carriers but also affected dogs, as they may not show obvious signs.  Carriers have one mutant and one normal gene and appear clinically normal, but they can pass the defective gene to their offspring.  Only a small number of Alaskan Klee Kai dogs have been tested thus far, and hence the frequency and bleeding tendency remain to be elucidated.

 

Screening Alaskan Klee Kai dogs with a clotting test (PT assay) may suggest FVII deficiency, and measurement of plasma FVII coagulant activity could confirm a diagnosis of FVII deficiency.  Results of the PT assay are normal for carriers, and measurement of plasma FVII coagulant activity will not accurately identify carriers, as there is overlap of FVII activities between carrier and normal dogs. 

 

A mutation-based DNA test to screen Alaskan Klee Kai dogs (and Beagles) for FVII deficiency has been established at the Josephine Deubler Genetic Disease Testing Laboratory of the University of Pennsylvania School of Veterinary Medicine.  This test can clearly identify affected, carrier, and normal (also known as clear) Alaskan Klee Kai dogs.  We recommend testing of any Alaskan Klee Kai dog with signs of bleeding, as well as its relatives.  Furthermore, it is advisable to screen any Alaskan Klee Kai dog, particularly popular sires, prior to breeding to limit the spread of this bleeding disorder.  Carriers could still be used in future breeding programs.  Knowing which dog is a carrier or normal (clear) will allow the targeted breeding of carriers with desirable traits to normal dogs without ever producing affected dogs, as long as the offspring are also tested and only clear dogs used thereafter. 

 

The Josephine Deubler Genetic Testing Laboratory at the University of Pennsylvania is offering screening for FVII deficiency in Alaskan Klee Kai dogs at a reduced introductory rate of $50 per dog through May 31, 2006, provided that a pedigree and adequate clinical information on the submission form are included ($75 per sample without pedigree).  Samples suitable for this DNA test include 1-2 mls EDTA-anticoagulated blood (preferable) or 3 cheek swabs (obtained with special cytology brushes).  Cytology brushes and test submission forms are available through the United Alaskan Klee Kai Association (http://www.uakka.com) and the Alaskan Klee Kai Association of America (http://akkaoa.org).  Test submission forms may also be downloaded from our website http://www.vet.upenn.edu/penngen.  For more information on canine FVII deficiency, please contact Dr. Beth Callan (215-898-3999; callan@vet.upenn.edu) or Dr. Urs Giger (215-898-8830; penngen@vet.upenn.edu).  Blood and dried cheek swab samples, along with test submission forms and pedigrees, may be submitted to Dr. Urs Giger/FVII Rm 4006, Ryan Veterinary Hospital, University of Pennsylvania, 3900 Delancey Street, Philadelphia, PA, 19104-6010.  Test results are generally available within 3 weeks of receipt of samples and are sent only to submitter of samples.  All information is kept strictly confidential.

 

 

 

As of 02.16.06

 

Factor VII (FVII) Deficiency is an inherited bleeding disorder caused by a deficiency of coagulation FVII. This clotting protein functions in the tissue juice system of coagulation. This genetic disorder has been well recognized for several decades in the commercial Beagle population**, where it manifests as a mild disorder associated with easy bruising.  The condition also occurs in an acquired form due to vitamin K deficiency or anticoagulant poisoning from rodent bait. Recently, however, there have been documented reports of abnormal bleeding from significant deficiency of FVII in a few Alaskan Klee Kai (AKK). 

 

Right now, the impact of this finding for the general AKK population is unknown, and there are questions to be answered.  One of these includes the ability to accurately assess the severity and prevalence of the disease in the AKK population.  While research is ongoing to identify a DNA test to address this question, there are some guidelines that breeders, and those with animals about to undergo surgical procedures, can follow to minimize risk to the dogs.

 

Based on guidelines suggested by Dr Jean Dodds, one of the first persons to describe FVII deficiency in animals years ago the following information should assist those who need practical information now.  This approach should be used until such time that a reliable DNA test is available.

 

Normal canine  FVII levels are 50-150%.

  1. Do not breed any animal with  FVII <25%.
  2. Do not breed any animal affected with FVII deficiency [i.e. a “bleeder”].
  3. You can breed a “carrier” (FVII between 26- 49 % but never showing clinical signs of  bleeding) with a dog that has FVII of at least 90%.
  4. Make sure that your breeding pair has at least one of them with FVII at least 90%, and the other one is no less than 25% (and not bleeding).
  5. If you have a dog about to undergo a surgical procedure, and is either a bleeder, or has a FVII of <25%, make sure that dog is given fresh- frozen plasma before and following surgery. The dose of plasma for each transfusion is 3-5 mL per pound of body weight.
  6. Puppies can be tested as early as 6 weeks of age.

 

Currently, the carrier status is not clearly defined by FVII levels.  However, these guidelines should provide a safe cushion for you and your dogs until we have tests that can more clearly distinguish the “affected” from the “carrier”.

 

Additionally, low testing animals may be at risk for illness later in life that affects the ability to clot.  This can include, among other factors, liver or kidney disease, low platelet counts or platelet function, medication for treatment of arthritis (non-steroidal anti-inflammatory drugs such as Rimadyl, Deramaxx, or Metacam) or other drugs that can affect clotting, such as aspirin, or other disease that may affect clotting times.  Periods of vaccination, viremia (viral illness), dental cleaning, or infection, or anything causing an inflammatory response in your dog may also affect clotting times.  The older a dog gets, the less resistance it may have to these health situations, and the marginal dog may become at greater risk for changes in overall clotting ability and from more fragile blood vessels.

 

A dog that presents with localized or generalized demodectic mange should be evaluated for FVII Deficiency, as the moist skin environment that results from decreased ability to maintain normal clotting status in the tissues provides a ripe environment for the mite infestation.

 

Another environmental factor that poses an additional risk for  any dog that spontaneously bleeds is access to rodenticides (rodent poisons).

 

Any AKK that presents with bruising or bleeding into the tissues from minor trauma, or with frank bleeding from dew claw removal or other surgery, should be evaluated for FVII Deficiency.

 

At this point in time, because there are no clear cut boundaries that distinguish between carrier vs affected vs non-carrier, non-affected status, the use of the previous guidelines, or using FVII levels to make breeding decisions, should be helpful.

 

Please see Figure 1.  This is a crude illustration that depicts the rationale for the levels used for making breeding decisions.

            Fig1:

 

These values can be obtained by:

  • Submitting citrated plasma sample from your dog to the Cornell University Diagnostic Laboratory, Comparative Coagulation Section (607-275-0622)
  • Include a copy of the dog’s pedigree (kept strictly confidential, but essential for this to be helpful to the researchers)

 

Forms for doing this include:

    1. Cover sheet with pricing info ($13 per test)
    2. Coagulation Sampling Flow Chart
    3. Sampling Instructions and Shipping Info
    4. General Submission Form

 

These can be accessed from AKKAOA’s website as well as UAKKA’s website.  They cannot be easily found on Cornell University’s website.  Anyone who needs copies mailed to you can contact Lo Binkley at lobink@adelphia.net or 805-379-0770/279-0771.

 

This has been a very scary several weeks for some of the AKK folks who have
dogs that are “affected” or “carriers”.  We all owe gratitude to Karen
Street, who has seen this all the way through to the point where there is an
identified potential problem in at least some of the breed.  We do not yet
know to what extent.

 

We also owe a great debt to the researchers at University of Wisconsin, Dr Marjory Brooks of Cornell University, which is the only place in the country that regularly quantifies FVII levels, and Dr Beth Callan’s group at the University of Pennsylvania that is working on the DNA aspect of this issue.  Many thanks also goes to Dr Jean Dodds for her patience in giving so much of her time to develop guidelines to help us address this problem now  ---  until we have a more specific genetic marker test upon which to make breeding decisions.

 

**Similar bleeding problems have been reported in the Malamute and “husky type” dogs.

 

Please do not contact the above-mentioned people, as we would not want to distract them from being able to focus on finding a solution to the AKK FVII problem.

 

 This information is being published jointly by AKKAOA and UAKKA.

Coagulation Sampling Flowchart

Lab Fees

Lab Form

Lab Sampling Instructions

 

The UNITED ALASKAN KLEE KAI ASSOCIATION (UAKKA) (originally known as The North East Alaskan Klee Kai Association) was formed to do everything possible to
protect, promote and advance the best interests, health and welfare of purebred Alaskan Klee Kai (AKK) and to continue to bring their natural qualities to
perfection through responsible breeding practices; and to promote the recognition and acceptance of the AKK as a separate and distinct breed of Nordic and Spitz heritage.

UAKKA, Inc